EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Female Sexual Health
Female sexual health has been historically underserved by pharmaceutical research—PT-141 (bremelanotide) was only the second drug ever approved for low sexual desire in women, and the first to work through a central nervous system mechanism rather than hormonal replacement. This conditions page collects the peptide compounds with published research relevant to female sexual function, fertility, hormonal regulation, and reproductive endocrinology.
The evidence is strong at the top—six FDA-approved drugs spanning desire, labor, fertility stimulation, and hormonal suppression—and drops rapidly. Kisspeptin-10 has genuine clinical-stage IVF data. Melanotan II has been self-administered by women for sexual effects despite having no female-specific clinical trial data.
Condition at a Glance
|
8 Compounds Researched |
6 FDA Approved |
1 Clinical Trials |
1 Pilot Data |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Pilot / Limited Human Data Small or preliminary human studies |
BLUF: Bottom Line Up Front
PT-141 is the headline: FDA-approved specifically for hypoactive sexual desire disorder in premenopausal women (Vyleesi, 2019). Two Phase 3 trials showed statistically significant improvement in desire and reduction in distress. Oxytocin is FDA-approved for labor and postpartum hemorrhage—the most widely used peptide in obstetrics worldwide. HMG is the workhorse of IVF ovarian stimulation. The GnRH agonists—Leuprolide, Nafarelin, Gonadorelin—are FDA-approved for endometriosis, central precocious puberty, and HPG axis suppression or diagnostics; all three are standard reproductive endocrinology tools. Kisspeptin-10 may eliminate ovarian hyperstimulation syndrome risk in IVF. Melanotan II has no published female sexual health data.
Compounds Researched for This Condition
8 compounds with published research relevant to female sexual health. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.
Group 1 of 4
The Approved Drugs
Three FDA-approved compounds with clinical data directly relevant to female sexual desire, childbirth, and fertility.
Group 2 of 4
The GnRH Analogs
Three FDA-approved GnRH analogs that suppress or stimulate the HPG axis—used in endometriosis, precocious puberty, IVF protocols, and hormonal diagnostic testing.
|
|
|
Group 3 of 4
The Pipeline
One compound with clinical-stage data that could change how IVF is practiced—eliminating its most dangerous complication.
|
Group 4 of 4
The Unregulated Option
One compound widely self-administered with no published female-specific clinical data.
|
What the Research Landscape Looks Like
The female sexual health landscape has two distinct stories. The first is reproductive medicine: oxytocin for labor, HMG for IVF stimulation, the GnRH agonists (Leuprolide, Nafarelin, Gonadorelin) for cycle suppression and endometriosis, and kisspeptin-10 for safer IVF triggers. These are standard-of-care or clinical-stage compounds with well-characterized mechanisms. The second story is sexual desire: PT-141’s FDA approval was a genuine breakthrough—the first CNS-mechanism drug for female HSDD—but the condition remains underserved, and the off-label use of Melanotan II reflects the gap between what is approved and what women are seeking.
The GnRH agonists share a counterintuitive mechanism: continuous receptor stimulation produces desensitization, which suppresses downstream sex hormone production. This makes them valuable for conditions driven by estrogen (endometriosis) or for temporarily shutting down the natural cycle (IVF). The melanocortin pathway is the novel element in desire pharmacology. PT-141 activates MC3R/MC4R receptors in the hypothalamus to modulate desire itself, not peripheral arousal mechanics. The RECONNECT trials demonstrated it works.
| Mechanism | Compounds |
|
Central Melanocortin Activation Activating brain melanocortin receptors to modulate sexual desire—a central nervous system mechanism independent of hormones. |
PT-141 (Bremelanotide), Melanotan II |
|
HPG Axis Modulation Acting on the hormonal cascade that controls estrogen, FSH, and LH—the core of reproductive endocrinology for fertility treatment, endometriosis, and IVF cycle suppression. |
HMG, Leuprolide, Nafarelin, Gonadorelin, Kisspeptin-10 |
|
Uterine Smooth Muscle Contraction Stimulating rhythmic uterine contractions for labor induction and controlling postpartum hemorrhage. |
Oxytocin |
Plain English
PT-141 is the breakthrough: the first drug approved for low sexual desire in women that works through the brain, not hormones. Oxytocin and HMG are reproductive medicine standards—labor induction and IVF. The GnRH agonists (Leuprolide, Nafarelin, Gonadorelin) shut down estrogen production to treat endometriosis and to control IVF cycles. Kisspeptin-10 could make IVF safer by eliminating OHSS risk. Melanotan II is used by women but has never been studied in women for sexual health.
Related Research
Research Clusters Covering These Compounds
|
Sexual Health & Hormonal Peptides The primary cluster—covering fertility, desire, and reproductive endocrinology. |
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.